Global Managed Access Program Cohort for Ligelizumab in CSU

Summary

Global Cohort Managed Access Program (MAP) to provide access to ligelizumab (QGE031) for chronic spontaneous urticaria (CSU)

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications